Clinical Trial

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion).
Protocol Amendment History 4 changes
notable Trial sites expanded: 9 -> 13 locations 2026-06-19
notable Trial sites expanded: 4 -> 8 locations 2026-05-28
critical Recruitment opened 2026-04-28
notable Trial sites expanded: 0 -> 3 locations 2026-04-28
Trial Details
NCT Number NCT07414836
Lead Sponsor BeOne Medicines
Conditions Advanced Solid Tumor
Enrollment 84 participants
Start Date 2026-04-13
Primary Completion 2029-04-30 (estimated)
Study Completion 2029-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-06